# OnCo record sclc-signalling (pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pathways/sclc-signalling/>
  a schema:BioChemEntity ;
  onco:kind "pathway" ;
  schema:identifier "sclc-signalling" ;
  schema:name "Small cell lung cancer (KEGG map)"@en ;
  schema:alternateName "KEGG hsa05222"@en, "Small cell lung cancer"@en ;
  schema:description "KEGG's small cell lung cancer map shows a tumour with both master brakes removed, RB1 and TP53, plus amplified MYC pushing the cell cycle and PTEN loss and BCL2 keeping cells alive. Chemotherapy with PD-L1 antibodies and the DLL3 T-cell engager tarlatamab are the current answers."@en ;
  schema:url <https://onco.cc/pathways/sclc-signalling/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.kegg.jp/pathway/hsa05222>, <https://doi.org/10.1038/s41572-020-00235-0> ;
  onco:related <https://onco.cc/pathways/lineage-plasticity-neuroendocrine/>, <https://onco.cc/pathways/p53-cell-cycle/> ;
  onco:cancers <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/nsclc/> ;
  onco:targets <https://onco.cc/targets/cdk4-6/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/akt/>, <https://onco.cc/targets/bcl2/>, <https://onco.cc/targets/rxr/> ;
  onco:drugs <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/serplulimab/>, <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/drugs/lurbinectedin/>, <https://onco.cc/drugs/topotecan/>, <https://onco.cc/drugs/ifinatamab-deruxtecan/> ;
  onco:pathways <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/cell-cycle-engine-cdks/>, <https://onco.cc/pathways/apoptosis-bcl2/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/lineage-plasticity-neuroendocrine/>, <https://onco.cc/pathways/transcription-addiction/>, <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-rudin-nat-rev-dis-primers/> .